Cantor Fitzgerald Reiterates Overweight Rating on Cartesian Therapeutics (RNAC)

Cantor Fitzgerald analyst Kristen Kluska reiterated an Overweight rating and $22.00 price target on Cartesian Therapeutics (NASDAQ: RNAC).

The analyst commented, “We are updating our RNAC model for the period ending December 31, 2024. We updated our model for the quarter and updated our operating expense estimates based on company guidance/actual numbers reported in the quarter. There were no changes to our 12-month PT of $22.”

For an analyst ratings summary and ratings history on Cartesian Therapeutics click here. For more ratings news on Cartesian Therapeutics click here.

Shares of Cartesian Therapeutics closed at $15.80 yesterday.

You May Also Be Interested In

• Anthropic Said In Talks To Buy Ai Startup Decart For $6 Billion - Bloomberg
• Park Dental Partners, Inc. (PARK) Tops Q2 EPS by 28c
• Acrivon Therapeutics, Inc. (ACRV) Tops Q2 EPS by 21c